Identification and Validation of Tumor-specific T Cell Receptors from Tumor Infiltrating Lymphocytes Using Tumor Organoid Co-cultures

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2024 Jul 2

PMID 38954022

Authors

Zhilang Li

Lisha Ma

Zhaoya Gao

Xiya Wang

Xuan Che

Pengchong Zhang

Yixian Li

Qianjing Zhang

Tianxing Liu

Yuan Sun

Yun Bai

Hongkui Deng

Affiliations

Soon will be listed here.

Abstract

T cell receptor-engineered T cells (TCR-Ts) therapy is promising for cancer immunotherapy. Most studies have focused on identifying tumor-specific T cell receptors (TCRs) through predicted tumor neoantigens. However, current algorithms for predicting tumor neoantigens are unreliable and many neoantigens are derived from non-coding regions. Thus, the technological platform for identifying tumor-specific TCRs using natural antigens expressed on tumor cells is urgently needed. In this study, tumor organoids-enriched tumor infiltrating lymphocytes (oeT) were obtained by repeatedly stimulation of autologous patient-derived organoids (PDO) in vitro. The oeT cells specifically responded to autologous tumor PDO by detecting CD137 expression and the secretion of IFN-γ using enzyme-linked immunospot assay. The measurement of oeT cell-mediated killing of three-dimensional organoids was conducted using a caspase3/7 flow cytometry assay kit. Subsequently, tumor-specific T cells were isolated based on CD137 expression and their TCRs were identified through single-cell RT-PCR analysis. The specificity cytotoxicity of TCRs were confirmed by transferring to primary peripheral blood T cells. The co-culture system proved highly effective in generating CD8 tumor-specific oeT cells. These oeT cells effectively induced IFN-γ secretion and exhibited specificity in killing autologous tumor organoids, while not eliciting a cytotoxic response against normal organoids. The analysis conducted by TCRs revealed a significant expansion of T cells within a specific subset of TCRs. Subsequently, the TCRs were cloned and transferred to peripheral blood T cells generation engineered TCR-Ts, which adequately recognized and killed tumor cell in a patient-specific manner. The co-culture system provided an approach to generate tumor-specific TCRs from tumor-infiltrating lymphocytes of patients with colorectal cancer, and tumor-specific TCRs can potentially be used for personalized TCR-T therapy.

References

Tran E, Robbins P, Rosenberg S . 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol. 2017; 18(3):255-262. PMC: 6295671. DOI: 10.1038/ni.3682. View

Tan Q, Zhang C, Yang W, Liu Y, Heyilimu P, Feng D . Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma. J Immunother Cancer. 2019; 7(1):232. PMC: 6714102. DOI: 10.1186/s40425-019-0709-7. View

Rosenberg S, Packard B, Aebersold P, Solomon D, Topalian S, TOY S . Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988; 319(25):1676-80. DOI: 10.1056/NEJM198812223192527. View

Parkhurst M, Yang J, Langan R, Dudley M, Nathan D, Feldman S . T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2010; 19(3):620-6. PMC: 3048186. DOI: 10.1038/mt.2010.272. View

Duhen T, Duhen R, Montler R, Moses J, Moudgil T, de Miranda N . Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun. 2018; 9(1):2724. PMC: 6045647. DOI: 10.1038/s41467-018-05072-0. View

Inozume T, Hanada K, Wang Q, Ahmadzadeh M, Wunderlich J, Rosenberg S . Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J Immunother. 2010; 33(9):956-64. PMC: 2980947. DOI: 10.1097/CJI.0b013e3181fad2b0. View

Seliger B, Harders C, Lohmann S, Momburg F, Urlinger S, Tampe R . Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts. Eur J Immunol. 1998; 28(1):122-33. DOI: 10.1002/(SICI)1521-4141(199801)28:01<122::AID-IMMU122>3.0.CO;2-F. View

Kopper O, de Witte C, Lohmussaar K, Espejo Valle-Inclan J, Hami N, Kester L . An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med. 2019; 25(5):838-849. DOI: 10.1038/s41591-019-0422-6. View

Dijkstra K, Cattaneo C, Weeber F, Chalabi M, van de Haar J, Fanchi L . Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. Cell. 2018; 174(6):1586-1598.e12. PMC: 6558289. DOI: 10.1016/j.cell.2018.07.009. View

10.

Li G, Bethune M, Wong S, Joglekar A, Leonard M, Wang J . T cell antigen discovery via trogocytosis. Nat Methods. 2019; 16(2):183-190. PMC: 6719556. DOI: 10.1038/s41592-018-0305-7. View

11.

Liu T, Tan J, Wu M, Fan W, Wei J, Zhu B . High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39CD8 T cells. Gut. 2020; 70(10):1965-1977. PMC: 8458084. DOI: 10.1136/gutjnl-2020-322196. View

12.

Leidner R, Sanjuan Silva N, Huang H, Sprott D, Zheng C, Shih Y . Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. N Engl J Med. 2022; 386(22):2112-2119. PMC: 9531755. DOI: 10.1056/NEJMoa2119662. View

13.

Zheng C, Fass J, Shih Y, Gunderson A, Sanjuan Silva N, Huang H . Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers. Cancer Cell. 2022; 40(4):410-423.e7. DOI: 10.1016/j.ccell.2022.03.005. View

14.

Dash P, Wang G, Thomas P . Single-Cell Analysis of T-Cell Receptor αβ Repertoire. Methods Mol Biol. 2015; 1343:181-97. DOI: 10.1007/978-1-4939-2963-4_15. View

15.

Malekzadeh P, Yossef R, Cafri G, Paria B, Lowery F, Jafferji M . Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens. Clin Cancer Res. 2020; 26(6):1267-1276. PMC: 7424598. DOI: 10.1158/1078-0432.CCR-19-1874. View

16.

Demmers L, Kretzschmar K, Van Hoeck A, Bar-Epraim Y, van den Toorn H, Koomen M . Single-cell derived tumor organoids display diversity in HLA class I peptide presentation. Nat Commun. 2020; 11(1):5338. PMC: 7577990. DOI: 10.1038/s41467-020-19142-9. View

17.

Beshiri M, Tice C, Tran C, Nguyen H, Sowalsky A, Agarwal S . A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening. Clin Cancer Res. 2018; 24(17):4332-4345. PMC: 6125202. DOI: 10.1158/1078-0432.CCR-18-0409. View

18.

Purbhoo M, Li Y, Sutton D, Brewer J, Gostick E, Bossi G . The HLA A*0201-restricted hTERT(540-548) peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor. Mol Cancer Ther. 2007; 6(7):2081-91. DOI: 10.1158/1535-7163.MCT-07-0092. View

19.

Tran E, Ahmadzadeh M, Lu Y, Gros A, Turcotte S, Robbins P . Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015; 350(6266):1387-90. PMC: 7445892. DOI: 10.1126/science.aad1253. View

20.

Robbins P, Kassim S, Tran T, Crystal J, Morgan R, Feldman S . A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2014; 21(5):1019-27. PMC: 4361810. DOI: 10.1158/1078-0432.CCR-14-2708. View